1. Home
  2. RGEN vs HALO Comparison

RGEN vs HALO Comparison

Compare RGEN & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGEN
  • HALO
  • Stock Information
  • Founded
  • RGEN 1981
  • HALO 1998
  • Country
  • RGEN United States
  • HALO United States
  • Employees
  • RGEN N/A
  • HALO N/A
  • Industry
  • RGEN Medical/Dental Instruments
  • HALO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • RGEN Health Care
  • HALO Health Care
  • Exchange
  • RGEN Nasdaq
  • HALO Nasdaq
  • Market Cap
  • RGEN 8.0B
  • HALO 7.4B
  • IPO Year
  • RGEN N/A
  • HALO N/A
  • Fundamental
  • Price
  • RGEN $120.21
  • HALO $54.23
  • Analyst Decision
  • RGEN Buy
  • HALO Buy
  • Analyst Count
  • RGEN 12
  • HALO 9
  • Target Price
  • RGEN $172.67
  • HALO $63.56
  • AVG Volume (30 Days)
  • RGEN 811.4K
  • HALO 3.3M
  • Earning Date
  • RGEN 04-29-2025
  • HALO 05-06-2025
  • Dividend Yield
  • RGEN N/A
  • HALO N/A
  • EPS Growth
  • RGEN N/A
  • HALO 55.40
  • EPS
  • RGEN N/A
  • HALO 3.76
  • Revenue
  • RGEN $650,429,000.00
  • HALO $1,084,306,000.00
  • Revenue This Year
  • RGEN $13.93
  • HALO $25.77
  • Revenue Next Year
  • RGEN $14.35
  • HALO $18.01
  • P/E Ratio
  • RGEN N/A
  • HALO $14.40
  • Revenue Growth
  • RGEN 4.88
  • HALO 25.64
  • 52 Week Low
  • RGEN $102.97
  • HALO $42.01
  • 52 Week High
  • RGEN $182.52
  • HALO $70.51
  • Technical
  • Relative Strength Index (RSI)
  • RGEN 39.75
  • HALO 41.37
  • Support Level
  • RGEN $120.11
  • HALO $47.50
  • Resistance Level
  • RGEN $129.42
  • HALO $53.95
  • Average True Range (ATR)
  • RGEN 6.22
  • HALO 3.31
  • MACD
  • RGEN -0.97
  • HALO -0.96
  • Stochastic Oscillator
  • RGEN 0.43
  • HALO 23.10

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Share on Social Networks: